SUPPORTING OUR BUSINESS
Our Investors
MinervaX is supported by international specialist healthcare investors and since inception in 2010 has raised around EUR 200 million from investor syndicates and from grants and loans from EU institutions.
Novo Holdings A/S
Board representative: Emmanuelle Coutanceau
Novo Holdings A/S manages the assets of the Novo Nordisk Foundation, one of the largest charitable foundations in the world. Novo Holdings provides seed and venture capital to development-stage companies, takes significant ownership positions in companies within life science and biotechnology, and manages a broad portfolio of financial assets.
Sunstone Capital
Board representative: Sten Verland
Sunstone Capital is an independent venture capital investor and one of the largest European venture capital investors with a focus on developing and expanding early-stage Life Science and Technology companies.
Wellington Partners
Board representative: Regina Hodits
Wellington Partners is a leading European venture capital firm investing in early- and growth-stage life science companies in biotechnology, therapeutics, medtech, diagnostics and digital health.
Sanofi Ventures
Board representative: Christopher Gagliardi
Sanofi Ventures is the corporate venture arm of Sanofi. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi including vaccines, oncology, immunology, rare diseases, potential cures in other core areas, and digital health solutions.
Adjuvant Capital
Board representative: Kabeer Aziz
Adjuvant Capital is a New York- and San Francisco-based life sciences investment fund with backing from prominent healthcare investors including Novartis, Merck, International Finance Corporation, and the Bill & Melinda Gates Foundation. Adjuvant invests in companies developing promising new vaccines, therapeutics, and diagnostics targeting high-burden infectious diseases, maternal and child health, and antimicrobial resistance, with a commitment to make these accessible to those who need them most in low- and middle-income countries.
Industrifonden
Board representative: Patrik Sobocki
Industrifonden is a Nordic venture capital investor based in Stockholm that invests in early-stage growth companies. Its areas of expertise include Life Sciences, Deep Tech, and Transformative Tech. In the life science space, Industrifonden focuses on biotech, healthtech, and medtech.
Trill Impact
Board representative: Bita Sehat
Trill Impact is a pioneering Impact House with a team of more than 35 experienced professionals based in the Nordics and Germany. Trill Impact aims to become a force for positive change and realize its vision of delivering real returns and lasting impact for the benefit of investors, businesses, and society at large.
Pureos Bioventures
Board representative: Veronica Gambillara Fonck
Pureos Bioventures is a venture capital fund advised by Swiss-based Pureos Partners that invests exclusively in private innovative drug development companies, with a particular emphasis on the next generation of biological drugs and drug formats. The fund’s portfolio companies develop therapies across a broad indication spectrum, including oncology, immunology, ophthalmology, rare diseases, and neuroscience.
EQT Life Sciences
Board representative: Vincent Brichard
EQT Life Sciences was formed in 2022 following the integration of LSP, a leading European life sciences and healthcare venture capital firm, into the EQT platform. With a dedicated team of highly experienced investment professionals, with backgrounds in medicine, science, business, and finance, EQT Life Sciences backs the smartest inventors who have ideas that could truly make a difference for patients.
OrbiMed
Board representative: Tal Zaks
OrbiMed is a specialist healthcare investment firm that invests globally across the healthcare industry through a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed’s team of over 100 professionals is based in New York City, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, London, and other key global markets.
LF Investment
LF Investment is the investment arm of The Lauritzen Foundation, which is parent company of the shipping companies J. Lauritzen and DFDS. LF Investment has holdings in companies in the oil analysis, measuring equipment, software, biotechnology, and real estate sectors.